Deepbridge Capital, the tax-efficient investment manager, has confirmed its EIS and SEIS product range for the 2018/19 tax year.
- Deepbridge Technology Growth EIS.
- Deepbridge Life Sciences EIS.
- Deepbridge Innovation SEIS.
- Deepbridge Life Sciences SEIS.
The firm told GBI Magazine that having reviewed the propositions in light of the Patient Capital Review and subsequent changes to Government legislation, that it believes these propositions adhere entirely with Government intentions and the ‘spirit of EIS.’
Deepbridge has also confirmed that the Deepbridge Technology Growth EIS and Deepbridge Life Sciences EIS will usually deploy funds on a monthly basis with the SEIS propositions usually deploying twice a year.
During the last tax year, Deepbridge invested in a total of 43 innovative technology and life sciences companies, supporting over 400 jobs across those investments.
Ian Warwick, Managing Partner at Deepbridge, said: “Supporting growth-focused technology and medical innovation requires considerable experience and understanding of these unique sectors. Our ethos has always been about providing the funding alongside practical support and hands-on management that offers investee companies the best opportunity to survive and thrive – and thereby ultimately maximising the potential return to investors.
“Financial advisers and investors are increasingly utilising Deepbridge EIS and SEIS propositions as they seek to access our team’s experience and expertise of providing high quality growth-focused, and ‘Knowledge Intensive’, opportunities which are at the forefront of how we believe EIS funding should be utilised – supporting job creation, developing export opportunities and delivering economic and health efficiencies.”
